Epidemiological update: First imported case of MERS-CoV in Greece
On 18 April 2014, the Hellenic Centre for Disease Control and Prevention (KEELPNO) announced a laboratory confirmed case of MERS-CoV infection in a 69 year old male patient.
On 18 April 2014, the Hellenic Centre for Disease Control and Prevention (KEELPNO) announced a laboratory confirmed case of MERS-CoV infection in a 69 year old male patient. The individual is a Greek citizen, permanently residing in Jeddah, Saudi Arabia, who arrived in Athens on 17 April on a flight via Amman, Jordan. Close contact tracing is ongoing; there are no suspected or confirmed cases of MERS-CoV infection associated with this individual to date.
The individual first sought medical attention with signs of illness on 8 April in Jeddah and was discharged on 10 April with a diagnosis of probable typhoid fever. His wife was hospitalised in the same hospital in Jeddah from 31 March to 5 April with laboratory confirmed typhoid fever. He sought medical attention the same day of his arrival in Greece (17 April 2014) for prolonged fever and diarrhea.
The patient is currently in stable condition receiving antimicrobial therapy and oseltamivir.
As of 22 April 2014, 333 laboratory confirmed cases of MERS-CoV have been reported by local health authorities worldwide, including 107 deaths. Of these, only fifteen have been reported outside of the Middle East including only ten in Europe.
ECDC is working closely with KEELPNO, the World Health Organization and other international partners with regard to this public health event.
In earlier Rapid Risk Assessments, ECDC concluded that the risk of importation of MERS-CoV to the EU was expected to continue and the risk of secondary transmission in the EU remains low. ECDC is currently revisiting its Rapid Risk Assessment which will be published in the coming days.
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.Read more
Expert panel reviews neuraminidase inhibitors for the prevention and treatment of influenza
An ECDC expert opinion concludes that there is clear evidence supporting the use of neuraminidase inhibitors in the treatment and prevention of influenza. Moreover, the current recommendations in European countries on the use of the neuraminidase inhibitors oseltamivir and zanamivir are appropriate and should be applied by prescribing physicians.Read more
Epidemiological update: Review of influenza season 2016–2017 in the EU/EEA
The influenza season 2016–2017 has now come to an end in Europe. In week 17/2017, all EU/EEA countries reported low influenza activity and the positivity rate (proportion of influenza virus positives among all tested specimens) falling below the 10% benchmark to 9.9%. For the previous six weeks, almost all EU/EEA countries had reported low influenza activity.Read more